Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Schedule of Segment Information) (Details)

v3.23.1
Segment Information (Schedule of Segment Information) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Segment Reporting Information [Line Items]    
Net Revenue $ 12,429 $ 23,925
Cost of goods - product revenue (6,449) (8,203)
Research and development (39,506) (36,722)
Selling, general and administrative (25,341) (26,270)
Other income (expense) 3,722 (2,208)
Income tax (expense) benefit 0 0
Net loss (55,145) (49,478)
Dermatology Products Sales    
Segment Reporting Information [Line Items]    
Net Revenue 12,213 23,296
Cost of goods - product revenue (6,449) (8,203)
Research and development (2,033) (1,266)
Selling, general and administrative (13,291) (14,715)
Other income (expense) (575) (386)
Income tax (expense) benefit   (104)
Net loss (10,135) (1,378)
Pharmaceutical and Biotechnology Product Development    
Segment Reporting Information [Line Items]    
Net Revenue 216 629
Research and development (37,473) (35,456)
Selling, general and administrative (12,050) (11,555)
Other income (expense) 4,297 (1,822)
Income tax (expense) benefit   104
Net loss $ (45,010) $ (48,100)